Precigen, Inc. (PGEN): Price and Financial Metrics
GET POWR RATINGS... FREE!
PGEN POWR Grades
- Growth is the dimension where PGEN ranks best; there it ranks ahead of 85.91% of US stocks.
- PGEN's strongest trending metric is Growth; it's been moving up over the last 177 days.
- PGEN's current lowest rank is in the Stability metric (where it is better than 13.74% of US stocks).
PGEN Stock Summary
- With a year-over-year growth in debt of -52.91%, PRECIGEN INC's debt growth rate surpasses just 4.99% of about US stocks.
- Revenue growth over the past 12 months for PRECIGEN INC comes in at -23.35%, a number that bests just 7.94% of the US stocks we're tracking.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PGEN comes in at 34.44% -- higher than that of 95.75% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to PRECIGEN INC, a group of peers worth examining would be GTHX, OPNT, ACAD, SPRO, and VYNE.
- Visit PGEN's SEC page to see the company's official filings. To visit the company's web site, go to www.precigen.com.
PGEN Valuation Summary
- PGEN's EV/EBIT ratio is 11.4; this is 15.15% higher than that of the median Healthcare stock.
- Over the past 115 months, PGEN's EV/EBIT ratio has gone up 34.8.
Below are key valuation metrics over time for PGEN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PGEN | 2023-01-20 | 5.5 | 2.9 | 16.3 | 11.4 |
| PGEN | 2023-01-19 | 5.3 | 2.8 | 15.8 | 11.0 |
| PGEN | 2023-01-18 | 5.8 | 3.1 | 17.3 | 12.1 |
| PGEN | 2023-01-17 | 5.7 | 3.1 | 17.1 | 12.0 |
| PGEN | 2023-01-13 | 5.5 | 2.9 | 16.4 | 11.5 |
| PGEN | 2023-01-12 | 4.8 | 2.6 | 14.4 | 10.1 |
PGEN Growth Metrics
- Its year over year cash and equivalents growth rate is now at 47.4%.
- Its 3 year net cashflow from operations growth rate is now at 57.72%.
- The 2 year revenue growth rate now stands at 14.56%.
The table below shows PGEN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 75.875 | -64.238 | 25.459 |
| 2022-06-30 | 80.714 | -57.447 | -91.684 |
| 2022-03-31 | 111.383 | -58.17 | -94.099 |
| 2021-12-31 | 103.873 | -55.771 | -92.166 |
| 2021-09-30 | 98.985 | -57.651 | -108.793 |
| 2021-06-30 | 101.007 | -59.633 | -108.537 |
PGEN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PGEN has a Quality Grade of C, ranking ahead of 33.59% of graded US stocks.
- PGEN's asset turnover comes in at 0.277 -- ranking 449th of 561 Business Services stocks.
- V, GOVX, and CELP are the stocks whose asset turnover ratios are most correlated with PGEN.
The table below shows PGEN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.277 | 0.456 | -0.241 |
| 2021-03-31 | 0.276 | 0.439 | -0.310 |
| 2020-12-31 | 0.291 | 0.462 | -0.418 |
| 2020-09-30 | 0.237 | 0.398 | -0.717 |
| 2020-06-30 | 0.201 | 0.376 | -0.731 |
| 2020-03-31 | 0.183 | 0.387 | -0.659 |
PGEN Price Target
For more insight on analysts targets of PGEN, see our PGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $9.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
PGEN Stock Price Chart Interactive Chart >
PGEN Price/Volume Stats
| Current price | $1.64 | 52-week high | $2.90 |
| Prev. close | $1.62 | 52-week low | $1.12 |
| Day low | $1.61 | Volume | 4,320,800 |
| Day high | $1.70 | Avg. volume | 2,037,633 |
| 50-day MA | $1.71 | Dividend yield | N/A |
| 200-day MA | $1.76 | Market Cap | 341.37M |
Precigen, Inc. (PGEN) Company Bio
Precigen, Inc. (formerly Intrexon Corporation) provides synthetic biology services. The Company designs and produces modular DNA control systems and applications for human therapeutics, protein production, industrial products, agricultural biotechnology, and animal sciences. The company was founded in 1998 and is based in Germantown, Maryland.
Latest PGEN News From Around the Web
Below are the latest news stories about PRECIGEN INC that investors may wish to consider to help them evaluate PGEN as an investment opportunity.
Sonoma, First Wave top healthcare gainers; Precigen, Baudax Bio among losers |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayIt's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday! |
Precigen Announces Pricing of $75.0 Million Public Offering of Common StockPrecigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has also granted the underwriters a 30-day option to purchase up to an additional 6,428,571 shares of its common stock. Gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $75.0 million, excluding any exerc |
Precigen Announces Proposed $75.0 Million Public Offering of Common StockPrecigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In addition, Precigen intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. All of the shares in the proposed offering a |
Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory PapillomatosisPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announces positive Phase 1 dose escalation and expansion cohort data as of the January 12, 2023 cutoff for the investigational, potential first-in-class PRGN-2012 off-the-shelf (OTS) AdenoVerse™ immunotherapy in patients with recurrent respiratory papillomatosis (RRP). |
PGEN Price Returns
| 1-mo | 16.31% |
| 3-mo | 1.86% |
| 6-mo | 6.49% |
| 1-year | -33.33% |
| 3-year | -68.46% |
| 5-year | -88.36% |
| YTD | 7.89% |
| 2022 | -59.03% |
| 2021 | -63.63% |
| 2020 | 86.13% |
| 2019 | -16.21% |
| 2018 | -43.23% |
Loading social stream, please wait...